Bausch Health Companies Stock Market Outlook

Stocks . USA . 
Stock . Bausch Health Companies
BHC Stock  USD 5.37  -0.38  -6.61%   
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. About 62% of recent sentiment around Bausch Health has been slightly more constructive than defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for Bausch Health Companies slightly above neutral at this time.
Investor Comfort Level
PanicConfidence
62 · Interested

Elasticity to Hype and News Sentiment

Bausch Health Companies news coverage registers positive at 71%, a data point that gauges whether public narrative is leading or lagging the business reality. Shifts in news tone at this level often precede a change in trading character that warrants attention.
Over a 90-day investment horizon, with an above-average risk tolerance, the model output for Bausch Health Companies is 'Strong Sell'. The Bausch Health buy-or-sell recommendation is derived from the selected investment horizon and risk tolerance parameters for Bausch Health.
  

Run Bausch Health Outlook Model

Our Bausch Health outlook engine provides a data-driven supplement to the analyst consensus on Bausch Health Companies. Macroaxis has no vested interest in Bausch Health Companies or any other instrument analyzed here. Multiple quantitative inputs drive the Bausch Health's signal across different market conditions.

How This Model Works

The recommendation output for Bausch Health is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.

  • Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
  • Current setup - Three Months with a risk setting described as I am an educated risk taker
  • Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates

Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.

Time Horizon

Risk Tolerance

Update Outlook
SellBuy
Strong Sell

Market Performance

WeakeningDetails

Volatility

StableDetails

Current Valuation

Below Model EstimateDetails

Odds Of Distress

ElevatedDetails

Economic Sensitivity

Shows low sensitivity to market movementsDetails

Investor Sentiment

InterestedDetails

Analyst Consensus

HoldDetails

Financial Strenth (F Score)

StrongDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Possible ManipulatorDetails
Bausch Health's current outlook reflects a cautious setup, where negative margins limit earnings-based valuation support, while contained volatility and stable operating conditions provide partial offset. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. For the selected horizon, Bausch Health yields Mean Deviation of 2.0, Standard Deviation of 2.53, and Variance of 6.39, which weigh on the current risk-reward outlook.
This model-based assessment for Bausch Health combines fundamental quality metrics with price behavior and the current analyst outlook to produce an integrated outlook. For additional context on this mid-cap stock in the Health Care sector, analyze the full set of Bausch Health reported fundamentals, including the relationship between the price to sales ttm and net income ttm. Bausch Health Companies has a number of shares shorted of 6.28 M. Its market performance and bankruptcy risk for the current cycle warrant close attention.

Recent Events and Market Context

The events below reflect recent headlines associated with Bausch Health. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.

Returns Distribution Density

Plotting Bausch Health's daily returns in a distribution reveals the day-to-day behavior of Bausch Health. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward.
Mean Return
-0.0666
Value At Risk
-4.12
Potential Upside
3.34
Standard Deviation
2.53
   Return Density   
       Distribution  
Risk management for Bausch Health depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for Bausch Health. Portfolio managers weigh the trade-offs across risk-return profiles.

Top Institutional Investors

Bausch Health Companies's institutional and insider mix shapes how the stock trades around earnings. Annual revenue is about 10.45 billion. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. Watching turnover and volume trends alongside ownership data adds depth to the picture.
Shares
Norges Bank2025-12-31
3.7 M
Dimensional Fund Advisors, Inc.2026-03-31
3.6 M
Macquarie Group Ltd2025-12-31
3.2 M
Arrowstreet Capital Limited Partnership2025-12-31
2.7 M
Charles Schwab Investment Management Inc2025-12-31
2 M
Private Management Group Inc2025-12-31
1.9 M
Millennium Management Llc2025-12-31
1.8 M
Geode Capital Management, Llc2025-12-31
1.7 M
D. E. Shaw & Co Lp2025-12-31
1.7 M
Paulson & Company Inc2025-12-31
73.3 M
Vanguard Group Inc2025-12-31
10.7 M
At 2.02 billion, Bausch Health Companies sits in mid-cap territory where institutional context matters most alongside valuation and volatility readings. Whether Bausch Health Companies institutional base is index-driven or conviction-based changes how to read it - at this size active managers often hold meaningful weight.
Backtest Bausch Health Companies

Key Drivers of Volatility and Market Exposure

Like most traded instruments, Bausch Health reflects both market risk and company or sector-specific developments. Diversifying across uncorrelated assets may reduce specific volatility, but broader stock market fluctuations remain influential. Mean Deviation for Bausch Health Companies remained near 2.00, alongside Option Implied Volatility close to 0.64 and Standard Deviation close to 2.53.
α
Alpha over Dow Jones		-0.083
β
Beta against Dow Jones-0.3816
σ
Overall volatility		2.49
Ir
Information ratio -0.0237
Bausch Health Companies return patterns indicate measurable variability compared to typical market movement. Bausch Health Companies has a beta of -0.3816, which suggests lower sensitivity to market-wide moves. Current implied volatility is around 64.0%, reflecting how the options market is pricing near-term uncertainty. The current Sharpe ratio of -0.0419 reflects returns below the risk-free rate.

Fundamentals Vs Peers

Bausch Health is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether Bausch Health generates superior or inferior returns relative to similar stocks. Divergence between Bausch Health's valuation multiples and its peer group flags either mispricing or a structural difference in quality.
    
 Better Than Average     
    
 Worse Than Average Compare Bausch Health to competition
FundamentalsBausch HealthPeer Average
Return On Equity TTM0.44-0.31
Return On Asset TTM0.0593-0.14
Profit Margin TTM-0.11-1.27
Operating Margin TTM0.21-5.51
Current Valuation21.65 B16.62 billion
Shares Outstanding373.48 M571.82 million
Shares Owned By Insiders30.40 %10.09 %
Shares Owned By Institutions66.23 %39.21 %
Number Of Shares Shorted6.28 M4.71 million
Price To Earnings TTM9.26 X28.72 X
Price To Book TTM18.78 X9.51 X
Price To Sales TTM0.19 X11.42 X
Revenue TTM10.45 B9.43 billion
Gross Profit TTM7.48 B27.38 billion
EBITDA TTM3.45 B3.9 billion
Net Income TTM120 M570.98 million
Cash And Equivalents TTM1.31 B2.7 billion
Cash Per Share TTM1.34 X5.01 X
Total Debt TTM21.21 B5.32 billion
Current Ratio TTM1.05 X2.16 X
Book Value Per Share TTM-5.51 X1,931
Cash Flow From Operations TTM1.4 B971.22 million
Short Ratio TTM4.73 X4.00 X
Earnings Per Share-3.24 X3.12 X
Price To Earnings To Growth0.01 X4.89 X
Target Price7.57N/A
Number Of Employees20.3 K18,840
Trailing Beta0.42-0.15
Market Capitalization TTM2.02 B19.03 billion
Total Asset TTM26.32 B29.47 billion
Retained Earnings TTM-9.65 B9.33 billion
Working Capital TTM1.98 B1.48 billion
Current Asset TTM984.02 M9.34 billion
Note: Disposition of 4420 shares by Seana Carson of Bausch Health at 5.77 subject to Rule 16 b-3 [view details]

Market Momentum

RSI at 44 (mildly bearish) and beta of -0.3816 together frame Bausch Health Companies momentum profile - showing how the stock is positioned relative to its own trend and the broader market. That inverse market relationship means conventional momentum frameworks need adjustment.
Accumulation Distribution0.0764
Daily Balance Of Power-0.86
Rate Of Daily Change0.93
Day Median Price5.54
Day Typical Price5.48
Market Facilitation Index0.44
Price Action Indicator-0.36
Period Momentum Indicator-0.38
Relative Strength Index44.2

Current Target Price Consensus

Bausch Health's target price is built from the average of all analyst forecasts we collect. Analyst performance can only be meaningfully measured through historical attribution analysis. The Bausch Health's target price data below warrants integration with other forecasting methods for a complete picture.
   7  Hold
The standard cadence for Bausch Health analyst updates is quarterly. Alongside each rating, analysts provide a target price reflecting their intrinsic value estimate for the stock. The analytical process involves reviewing Bausch Health Companies's financial filings and listening to conference calls.
Exposure   Valuation

Bausch Health Target Price Projection

The market currently values Bausch Health at 5.37, while analysts project a target of 7.57. The market price shows where Bausch Health Companies trades today; the target shows where analysts expect the stock to go. The greater the spread between these prices, the stronger the incentive for investors to act.

Current Price

Bausch Health Market Quote on 13th of May 2026

Low Price5.32Odds
High Price5.76Odds

5.37

Target Price

Analyst Consensus On Bausch Health Target Price

Low Estimate6.89Odds
High Estimate8.4Odds

7.57

Historical Lowest Forecast  6.89 Target Price  7.57 Highest Forecast  8.4
Price target estimates for Bausch Health are generally included in analyst research reports. Even though the financial press often picks up these targets promptly, a delay may still exist. Bausch Health's price target data shown here is sourced from published analyst reports and updated periodically.

Bausch Health Analyst Ratings

Bausch Health draws a Hold consensus from the 7 analysts tracking it. Sentiment is mixed, with 1 rates it favorably. Across the board, mixed sentiment dominates Bausch Health's analyst landscape.

Analyst Consensus Breakdown

Average Consensus Estimates

Recommendation Framework, Assumptions & Editorial Oversight

The model output for Bausch Health reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Bausch Health include P/E of 9.26, ROE of 43.64%. External analyst coverage is currently summarized as Hold across 7 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as models are revised.

Reported values for Bausch Health Companies are derived from periodic company reporting and market reference feeds and standardized for analysis. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.

Editorial Review & Methodology Oversight

Vlad Skutelnik
Role: Macroaxis Contributor
Finance background: Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.
Last reviewed on May 8th, 2026

Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.